Clarity Wealth Advisors LLC Increases Stake in Johnson & Johnson (NYSE:JNJ)

Clarity Wealth Advisors LLC lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 23,938 shares of the company’s stock after acquiring an additional 969 shares during the quarter. Johnson & Johnson accounts for approximately 1.3% of Clarity Wealth Advisors LLC’s portfolio, making the stock its 25th largest holding. Clarity Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $3,787,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. AMI Investment Management Inc. boosted its holdings in Johnson & Johnson by 3.8% in the 1st quarter. AMI Investment Management Inc. now owns 22,018 shares of the company’s stock valued at $3,483,000 after purchasing an additional 810 shares in the last quarter. Chatham Capital Group Inc. boosted its stake in shares of Johnson & Johnson by 0.6% in the first quarter. Chatham Capital Group Inc. now owns 51,194 shares of the company’s stock valued at $8,098,000 after buying an additional 309 shares in the last quarter. Waterway Wealth Management LLC acquired a new position in Johnson & Johnson during the first quarter worth $822,000. Strata Wealth Advisors LLC raised its position in Johnson & Johnson by 219.2% in the first quarter. Strata Wealth Advisors LLC now owns 5,927 shares of the company’s stock worth $938,000 after acquiring an additional 4,070 shares in the last quarter. Finally, Sandy Cove Advisors LLC lifted its holdings in Johnson & Johnson by 4.4% in the first quarter. Sandy Cove Advisors LLC now owns 5,597 shares of the company’s stock valued at $885,000 after acquiring an additional 238 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

JNJ has been the topic of a number of recent analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $175.00 price target on shares of Johnson & Johnson in a research note on Monday, June 17th. Bank of America lowered their target price on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Monday. HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and raised their price objective for the company from $169.00 to $170.00 in a research note on Thursday, April 18th. Finally, StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Sunday. Eight research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $174.07.

Johnson & Johnson Trading Up 0.2 %

Shares of JNJ stock opened at $146.42 on Tuesday. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $175.97. The company has a market capitalization of $352.39 billion, a price-to-earnings ratio of 9.13, a PEG ratio of 2.43 and a beta of 0.52. The firm has a 50-day moving average price of $148.14 and a 200 day moving average price of $154.05. The company has a current ratio of 1.17, a quick ratio of 0.94 and a debt-to-equity ratio of 0.36.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, beating analysts’ consensus estimates of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The business had revenue of $21.38 billion during the quarter, compared to analyst estimates of $21.39 billion. During the same quarter in the previous year, the business posted $2.68 earnings per share. The company’s revenue was up 2.3% on a year-over-year basis. Research analysts forecast that Johnson & Johnson will post 10.62 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st were given a $1.24 dividend. The ex-dividend date of this dividend was Monday, May 20th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.39%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s payout ratio is currently 30.92%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.